# 5-Hydroxytryptophan
*Source: https://psychonautwiki.org/wiki/5-Hydroxytryptophan*

## Dosage & Duration

### Oral

**Dosage:**
- Threshold: 25 mg
- Light: 50 - 100 mg
- Common: 100 - 300 mg
- Strong: 300 - 500 mg
- Heavy: 500 mg +

**Duration:**

**5-Hydroxytryptophan** (also known as **5-HTP** and **oxitriptan** ) is a naturally occurring chemical substance and a metabolic intermediate in the biosynthesis of [serotonin](https://psychonautwiki.org/wiki/Serotonin) in the human body. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]

5-HTP is available over the counter in the United States, United Kingdom, and Canada as a dietary supplement and is sometimes used as an [antidepressant](https://psychonautwiki.org/wiki/Antidepressant) , sleep aid, and appetite suppressant. It is marketed in some European countries as a prescription drug for the treatment of major depression.

5-HTP is also popularly consumed by users of [MDMA](https://psychonautwiki.org/wiki/MDMA) and other serotonin-releasing agents to try to reduce the negative [after effects](https://psychonautwiki.org/wiki/MDMA#After_effects) that begin during the substance's [come down](https://psychonautwiki.org/wiki/Duration) period, including [anxiety](https://psychonautwiki.org/wiki/Anxiety) , [depression](https://psychonautwiki.org/wiki/Depression) , and [cognitive fatigue](https://psychonautwiki.org/wiki/Cognitive_fatigue) . Since 5-HTP is a precursor for the neurotransmitter [serotonin](https://psychonautwiki.org/wiki/Serotonin) and MDMA administration both depletes serotonin levels in the brain as well as inhibit the enzyme needed to produce it (i.e. tryptophan hydroxylase) for a short period after, it is believed that taking 5-HTP in the days after coming down will speed up the production of serotonin and decrease the time needed to recover (though there are many popular misconceptions and controversies as to just how effective it is for this purpose). [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]

5-HTP should not be taken until 12 hours after one's last dose of MDMA because combining the two substances could interact to increase the brain's serotonin levels to dangerous levels, which can result in a potentially life-threatening condition called [serotonin syndrome](https://psychonautwiki.org/wiki/Serotonin_syndrome) .

## Chemistry

5-HTP or 5-Hydroxytryptophan is a synthetic indole alkaloid molecule of the [tryptamine](https://psychonautwiki.org/wiki/Tryptamine) class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R 3 to an amino group via an ethyl side chain. 5-HTP is substituted at R 5 of its indole heterocycle with a hydroxy (OH) functional group. It also contains propanoic acid group bound to the terminal amine R N of its tryptamine backbone. 5-HTP is the 5-hydroxy analog of [tryptophan](https://psychonautwiki.org/wiki/Tryptophan) , and is sold in its levorotary isomer form. 5-HTP contains the core structure of [serotonin](https://psychonautwiki.org/wiki/Serotonin) with the addition of a propanoic acid at R N , and is converted by the body into serotonin by metabolic reactions.

## Pharmacology

The psychoactive action of 5-HTP is derived from its increase in production of [serotonin](https://psychonautwiki.org/wiki/Serotonin) in central nervous system tissue. 5-HTP is decarboxylated to serotonin (5-hydroxytryptamine or 5-HT) by the enzyme 'aromatic-L-amino-acid decarboxylase', with the help of vitamin B 6 . This reaction occurs both in nervous tissue and in the liver. 5-HTP crosses the blood–brain barrier, while 5-HT (serotonin) does not.

Excess 5-HTP, especially when administered with vitamin B 6 , is thought to be metabolized and excreted.

## Subjective effects
### Physical effects
 
- For some individuals, 5-HTP can cause the following side effects (although rare, and typically at higher dosages). 
- **[Sedation](https://psychonautwiki.org/wiki/Sedation)**
- **[Stimulation](https://psychonautwiki.org/wiki/Stimulation)**
- **[Bodily control enhancement](https://psychonautwiki.org/wiki/Bodily_control_enhancement)**
- **[Abnormal heartbeat](https://psychonautwiki.org/wiki/Abnormal_heartbeat)**
- **[Appetite suppression](https://psychonautwiki.org/wiki/Appetite_suppression)**
- **[Diarrhea](https://psychonautwiki.org/wiki/Diarrhea)**
- **[Dizziness](https://psychonautwiki.org/wiki/Dizziness)**
- **[Ear ringing](/w/index.php?title=Ear_ringing&action=edit&redlink=1)**
- **[Headaches](https://psychonautwiki.org/wiki/Headaches)**
- **[Heartburn](/w/index.php?title=Heartburn&action=edit&redlink=1)**
- **[Increased blood pressure](https://psychonautwiki.org/wiki/Increased_blood_pressure)**
- **[Increased heart rate](https://psychonautwiki.org/wiki/Increased_heart_rate)**
- **[Nausea](https://psychonautwiki.org/wiki/Nausea) and vomiting**
- **[Stomach bloating](https://psychonautwiki.org/wiki/Stomach_bloating)**
- **[Stomach cramps](https://psychonautwiki.org/wiki/Stomach_cramps)**
- **[Teeth grinding](https://psychonautwiki.org/wiki/Teeth_grinding)** ### Visual effects
 
- Visual distortions have been reported at heavy doses and consistent usage of 5-HTP. They are usually mild. 
- **[Tracers](https://psychonautwiki.org/wiki/Tracers)**
- **[Color enhancement](https://psychonautwiki.org/wiki/Color_enhancement)**
- **[Drifting](https://psychonautwiki.org/wiki/Drifting)**
- **[Depth perception distortions](https://psychonautwiki.org/wiki/Depth_perception_distortions)** ### Cognitive effects
 
- - **[Cognitive euphoria](https://psychonautwiki.org/wiki/Cognitive_euphoria)** - Although mild, this effect is present at heavier dosages, but may also come with it a number of peripheral side effects due to peripheral serotonin activity (mostly on the gut).
- **[Anxiety suppression](https://psychonautwiki.org/wiki/Anxiety_suppression)**
- **[Memory enhancement](https://psychonautwiki.org/wiki/Memory_enhancement)**
- **[Mindfulness](https://psychonautwiki.org/wiki/Mindfulness)**
- **[Motivation enhancement](https://psychonautwiki.org/wiki/Motivation_enhancement)**
- **[Sleepiness](https://psychonautwiki.org/wiki/Sleepiness)**
- **[Thought acceleration](https://psychonautwiki.org/wiki/Thought_acceleration)** or **[Thought deceleration](https://psychonautwiki.org/wiki/Thought_deceleration)** ### After effects
 
- - **[Dream potentiation](https://psychonautwiki.org/wiki/Dream_potentiation)**
- **[Physical fatigue](https://psychonautwiki.org/wiki/Physical_fatigue)**
- **[Sleep paralysis](https://psychonautwiki.org/wiki/Sleep_paralysis)** ### Auditory effects
 
- - **[Hallucinations](https://psychonautwiki.org/wiki/Auditory_hallucinations)** - Auditory hallucinations have been reported on 5-HTP, however they are rare and only occur at high dosages.
### Experience reports

Anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) include:

- [Experience:5-Hydroxytryptophan (100mg, oral) - strong imagination](https://psychonautwiki.org/wiki/Experience:5-Hydroxytryptophan_(100mg,_oral)_-_strong_imagination)

Additional experience reports can be found here:

- [Erowid Experience Vaults: 5-HTP](https://www.erowid.org/experiences/subs/exp_Tryptophan_5HTP.shtml)

## Toxicity and harm potential

Due to the conversion of 5-HTP into serotonin by the liver, with prolonged use, there may be a significant risk of heart valve disease from serotonin's effect on the heart, which is thought to be due to agonism of the 5-HT 2B receptors present on it.

It has been suggested that 5-HTP may cause eosinophilia-myalgia syndrome (EMS), a serious condition which results in extreme muscle tenderness, myalgia, and blood abnormalities. However, there is evidence to show that EMS was likely caused by a contaminant in certain 5-HTP supplements instead of the substance itself.

### Dangerous interactions

Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each, but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Combinations in the list below may increase the amount of neurotransmitters, such as serotonin, to dangerous or even fatal levels, resulting in life-threatening [serotonin syndrome](https://psychonautwiki.org/wiki/Serotonin_syndrome) .

- **SSRIs** - When combined with antidepressants of the SSRI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.
- **SNRIs**
- **Serotonin releasers** such as **[MDMA](https://psychonautwiki.org/wiki/MDMA)** , **[mephedrone](https://psychonautwiki.org/wiki/Mephedrone)** , **[4-FA](https://psychonautwiki.org/wiki/4-FA)** , **[MDAI](https://psychonautwiki.org/wiki/MDAI)** and **[αMT](https://psychonautwiki.org/wiki/%CE%91MT)** - To prevent serotonin syndrome, 5-HTP should only be taken once the user has come down from the MDMA (or other serotonin releaser), roughly 12 hours after the last dose.
- **MAOIs** such as **[syrian rue](https://psychonautwiki.org/wiki/Syrian_rue)** , **[banisteriopsis caapi](https://psychonautwiki.org/wiki/Banisteriopsis_caapi)** , **[2C-T-2](https://psychonautwiki.org/wiki/2C-T-2)** , **[2C-T-7](https://psychonautwiki.org/wiki/2C-T-7)** , **[αMT](https://psychonautwiki.org/wiki/%CE%91MT)** , and some **[antidepressants](https://psychonautwiki.org/wiki/Antidepressants)** - When combined with antidepressants of the MAOI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.
- **Tricyclic antidepressants (TCAs)**
- **Tramadol**

## Legal status

5-HTP is commonly sold over the counter as a dietary supplement in the United States, United Kingdom, Canada and most of Europe and is not subject to any illicit substance control laws.

In some parts of Europe, where it prescribed as an anti-depressant, there may be some controls on its sale and distribution. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]

## See also

- [Serotonin syndrome](https://psychonautwiki.org/wiki/Serotonin_syndrome)
- [Tryptamine](https://psychonautwiki.org/wiki/Tryptamine)
- [Neurotransmitter](https://psychonautwiki.org/wiki/Neurotransmitter)
- [MDMA](https://psychonautwiki.org/wiki/MDMA)
- [MDAI](https://psychonautwiki.org/wiki/MDAI)
- [MDA](https://psychonautwiki.org/wiki/MDA)

## External links

- [5-Hydroxytryptophan (Wikipedia)](https://en.wikipedia.org/wiki/5-Hydroxytryptophan)
- [5-Hydroxytryptophan (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=5149)
- [5-Hydroxytryptophan (UM Medical Center)](http://umm.edu/health/medical/altmed/supplement/5hydroxytryptophan-5htp)
- [5-HTP (DrugBank)](https://go.drugbank.com/drugs/DB02959)
- [5-HTP (Examine.com)](https://examine.com/supplements/5-htp/)
- [5-HTP (Drugs.com)](https://www.drugs.com/npp/5-htp.html)

## References
1. ↑ Society, S. P. (2000).*Index Nominum 2000: International Drug Directory*. Taylor & Francis.[ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number)[9783887630751](http://en.wikipedia.org/wiki/Special:BookSources/9783887630751).
2. ↑ h Wang, X., Baumann, M. H., Dersch, C. M., Rothman, R. B. (10 August 2007).["Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of l-5-hydroxytryptophan"](https://www.sciencedirect.com/science/article/pii/S0306452207006732).*Neuroscience*.**148**(1): 212–220.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.neuroscience.2007.05.024](//doi.org/10.1016%2Fj.neuroscience.2007.05.024).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0306-4522](//www.worldcat.org/issn/0306-4522).
3. ↑ Stone, D. M., Johnson, M., Hanson, G. R., Gibb, J. W. (March 1989).["Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites"](https://linkinghub.elsevier.com/retrieve/pii/0922410689900485).*European Journal of Pharmacology: Molecular Pharmacology*.**172**(1): 93–97.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/0922-4106(89)90048-5](//doi.org/10.1016%2F0922-4106%2889%2990048-5).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0922-4106](//www.worldcat.org/issn/0922-4106).
4. ↑ Rahman, M. K., Nagatsu, T., Sakurai, T., Hori, S., Abe, M., Matsuda, M. (October 1982). "Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats".*Japanese Journal of Pharmacology*.**32**(5): 803–811.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1254/jjp.32.803](//doi.org/10.1254%2Fjjp.32.803).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0021-5198](//www.worldcat.org/issn/0021-5198).
5. ↑ Bouchard, S., Bousquet, C., Roberge, A. G. (September 1981). "Characteristics of dihydroxyphenylalanine/5-hydroxytryptophan decarboxylase activity in brain and liver of cat".*Journal of Neurochemistry*.**37**(3): 781–787.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1111/j.1471-4159.1982.tb12555.x](//doi.org/10.1111%2Fj.1471-4159.1982.tb12555.x).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0022-3042](//www.worldcat.org/issn/0022-3042).
6. ↑ Nakatani, Y., Sato-Suzuki, I., Tsujino, N., Nakasato, A., Seki, Y., Fumoto, M., Arita, H. (May 2008). "Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat".*The European Journal of Neuroscience*.**27**(9): 2466–2472.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1111/j.1460-9568.2008.06201.x](//doi.org/10.1111%2Fj.1460-9568.2008.06201.x).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1460-9568](//www.worldcat.org/issn/1460-9568).
7. ↑ Bouchard, S., Roberge, A. G. (1 July 1979).["Biochemical properties and kinetic parameters of dihydroxyphenyialanine – 5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat"](http://www.nrcresearchpress.com/doi/10.1139/o79-126).*Canadian Journal of Biochemistry*.**57**(7): 1014–1018.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1139/o79-126](//doi.org/10.1139%2Fo79-126).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0008-4018](//www.worldcat.org/issn/0008-4018).
8. ↑ Amamoto, T., Sarai, K. (September 1976). "On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression".*Hiroshima Journal of Medical Sciences*.**25**(2–3): 135–140.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0018-2052](//www.worldcat.org/issn/0018-2052).
9. ↑ Gustafsson, B. I., Tømmerås, K., Nordrum, I., Loennechen, J. P., Brunsvik, A., Solligård, E., Fossmark, R., Bakke, I., Syversen, U., Waldum, H. (29 March 2005). "Long-term serotonin administration induces heart valve disease in rats".*Circulation*.**111**(12): 1517–1522.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1161/01.CIR.0000159356.42064.48](//doi.org/10.1161%2F01.CIR.0000159356.42064.48).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1524-4539](//www.worldcat.org/issn/1524-4539).
10. ↑ Xu, J., Jian, B., Chu, R., Lu, Z., Li, Q., Dunlop, J., Rosenzweig-Lipson, S., McGonigle, P., Levy, R. J., Liang, B. (December 2002). "Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells".*The American Journal of Pathology*.**161**(6): 2209–2218.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0002-9440(10)64497-5](//doi.org/10.1016%2FS0002-9440%2810%2964497-5).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0002-9440](//www.worldcat.org/issn/0002-9440).
11. ↑ Michelson, D., Page, S. W., Casey, R., Trucksess, M. W., Love, L. A., Milstien, S., Wilson, C., Massaquoi, S. G., Crofford, L. J., Hallett, M. (December 1994). "An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan".*The Journal of Rheumatology*.**21**(12): 2261–2265.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0315-162X](//www.worldcat.org/issn/0315-162X).
12. ↑ 12.0 12.1 Ma, Z., Zhang, G., Jenney, C., Krishnamoorthy, S., Tao, R. (7 July 2008). "Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats".*European Journal of Pharmacology*.**588**(2–3): 198–206.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.ejphar.2008.04.004](//doi.org/10.1016%2Fj.ejphar.2008.04.004).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0014-2999](//www.worldcat.org/issn/0014-2999).
13. ↑ 13.0 13.1 Izumi, T., Iwamoto, N., Kitaichi, Y., Kato, A., Inoue, T., Koyama, T. (27 February 2006). "Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats".*European Journal of Pharmacology*.**532**(3): 258–264.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.ejphar.2005.12.075](//doi.org/10.1016%2Fj.ejphar.2005.12.075).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0014-2999](//www.worldcat.org/issn/0014-2999).NewPP limit report Cached time: 20251218075119 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.029 seconds CPU time usage: 0.329 seconds Real time usage: 0.702 seconds Preprocessor visited node count: 1506/1000000 Post‐expand include size: 85349/2097152 bytes Template argument size: 7787/2097152 bytes Highest expansion depth: 12/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 20650/5000000 bytes Lua time usage: 0.290/7 seconds Lua virtual size: 8.43 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 597.179 1 -total 40.04% 239.101 12 Template:Cite_journal 13.40% 80.031 3 Template:Citation_needed 12.83% 76.634 1 Template:Cite_book 11.76% 70.205 1 Template:SubstanceBox/5-HTP 11.68% 69.765 1 Template:Fix 10.96% 65.452 2 Template:Category_handler 10.51% 62.754 1 Template:SubstanceBox 9.38% 55.994 1 Template:Distinguish2 8.86% 52.925 1 Template:Hatnote